Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

2.

Radiation therapy for chemotherapy-resistant recurrent epithelial ovarian cancer.

Machida S, Takei Y, Yoshida C, Takahashi Y, Koyanagi T, Sato N, Taneichi A, Saga Y, Fujiwara H, Suzuki M.

Oncology. 2014;86(4):232-8. doi: 10.1159/000357269. Epub 2014 May 13.

PMID:
24853194
3.

Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy.

Fujiwara K, Suzuki S, Yoden E, Ishikawa H, Imajo Y, Kohno I.

Int J Gynecol Cancer. 2002 May-Jun;12(3):250-6.

PMID:
12060445
4.

Planning treatment for women with recurrent epithelial ovarian cancer.

Tanner E, Armstrong DK.

Oncology (Williston Park). 2013 Apr;27(4):304, 306. No abstract available.

5.

Management of recurrent EOC: the state of the art.

Fleming GF.

Oncology (Williston Park). 2013 Apr;27(4):298, 303-4. No abstract available.

6.

Combining targeted therapies in ovarian cancer.

Scambia G, Salutari V, Ferrandina G.

Lancet Oncol. 2014 Oct;15(11):1179-81. doi: 10.1016/S1470-2045(14)70421-8. Epub 2014 Sep 10. No abstract available.

PMID:
25218905
7.

The chemosensitivity of nodal metastases in recurrent epithelial ovarian cancer.

Kataoka F, Tsuda H, Nomura H, Chiyoda T, Tominaga E, Suzuki A, Susumu N, Aoki D.

Eur J Gynaecol Oncol. 2011;32(2):160-3.

PMID:
21614904
8.

Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study.

Gao Y, Liu Z, Chen X, Luo W, Zhang L, Wang J.

BMC Cancer. 2011 Oct 11;11:439. doi: 10.1186/1471-2407-11-439.

10.

Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently?

Friedlander ML, Stockler MR, Butow P, King MT, McAlpine J, Tinker A, Ledermann JA.

J Clin Oncol. 2013 Jun 20;31(18):2362. doi: 10.1200/JCO.2012.47.7927. Epub 2013 May 13. No abstract available.

PMID:
23669225
11.

[Effect of evidence-based medicine on the decision of chemotherapy for epithelial ovarian cancer].

Li GT.

Zhonghua Fu Chan Ke Za Zhi. 2012 Aug;47(8):582-6. Chinese. No abstract available.

PMID:
23141177
12.

Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab.

Dohrmann T, Kutup A, Mahner S, Müller V, Jaenicke F, Izbicki JR, Vashist YK.

J Clin Oncol. 2013 Apr 20;31(12):e208-10. doi: 10.1200/JCO.2012.45.1708. Epub 2013 Mar 18. No abstract available.

PMID:
23509305
13.

Bladder perforation in a patient with recurrent epithelial ovarian cancer after treatment with bevacizumab.

Bansal N, Hoffman M.

Gynecol Oncol. 2011 Feb;120(2):313-4. doi: 10.1016/j.ygyno.2010.10.002. Epub 2010 Nov 5. No abstract available.

PMID:
21055796
14.

Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives.

Lorusso D, Ferrandina G, Fruscella E, Marini L, Adamo V, Scambia G.

Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1002-13. Review.

PMID:
16343176
15.

Combined drug therapy for ovarian carcinoma.

Li MC, Hsu KP.

Clin Obstet Gynecol. 1970 Dec;13(4):928-44. Review. No abstract available.

PMID:
4325125
16.

Helical tomotherapy versus conventional radiation to deliver abdominopelvic radiation.

Choe J, Kulasekere R, Oddo D, Anthony S, Shin T, Murray M, Kunos CA.

Technol Cancer Res Treat. 2012 Feb;11(1):49-56.

PMID:
22181331
17.

Clinical application of oxaliplatin in epithelial ovarian cancer.

Fu S, Kavanagh JJ, Hu W, Bast RC Jr.

Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1717-32. Review.

PMID:
17009963
18.

Ovarian cancer: TRINOVA-1, beyond VEGF inhibition.

Villanueva MT.

Nat Rev Clin Oncol. 2014 Aug;11(8):442. doi: 10.1038/nrclinonc.2014.118. Epub 2014 Jul 8. No abstract available.

PMID:
25001464
19.

Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance.

Chuang YT, Chang CL.

Taiwan J Obstet Gynecol. 2012 Sep;51(3):336-41. doi: 10.1016/j.tjog.2012.07.003. Review.

Supplemental Content

Support Center